Lab
Absolute Diagnostics, LLC
Absolute Diagnostics, LLC was paid $225K by Medicaid between Oct 2021 and Jun 2023, across 33 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 39% of everything it billed.
33Billing provider infoABSOLUTE DIAGNOSTICS, LLC
WICHITA, KS 67205
WICHITA, KS 67205
33aNPI1568059368assigned 12/28/2020
33bProvider typeClinical Medical Laboratory
28Total paid$225K
24GClaims17,319
24DCodes billed33
24AFirst – last monthOct 2021 – Jun 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Kansas
Rank by total paid#15 of 47
Median peer was paid$64K
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 2,678 | $21K | |
| 2022 | 8,196 | $134K | |
| 2023 | 6,445 | $69K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 39% | 976 | 857 | $87K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20% | 2,852 | 935 | $44K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 20% | 208 | 189 | $44K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 6.3% | 2,836 | 927 | $14K |
| 87631 | 3.5% | 301 | 271 | $8K | |
| 87640 | 1.9% | 486 | 425 | $4K | |
| 87641 | 1.6% | 349 | 297 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.5% | 883 | 780 | $3K |
| 87581 | 1.1% | 548 | 490 | $2K | |
| 87486 | <1% | 439 | 386 | $2K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,002 | 353 | $2K |
| 87481 | <1% | 101 | 92 | $2K |
21 more codes
| 87500 | <1% | 209 | $2K | |
| 87653 | <1% | 169 | $1K | |
| 87563 | <1% | 150 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 621 | $729.27 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 610 | $484.30 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 185 | $470.95 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 178 | $422.60 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 375 | $370.96 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 123 | $366.71 |
| 87541 | <1% | 52 | $349.15 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 27 | $245.24 |
| 85027 | <1% | 242 | $243.63 | |
| 83719 | <1% | 138 | $212.78 | |
| 80061 | Lipid panel | <1% | 140 | $124.86 |
| 81001 | <1% | 115 | $48.20 | |
| 83735 | <1% | 56 | $40.64 | |
| 81003 | <1% | 42 | $8.73 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 964 | $0.05 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 183 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 1,717 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALLACE, RYAN (CEO)